Concepedia

Author

Barbara Schulz

Novartis (Switzerland)

Also Known As

B S Schulz, B Schulz, B. S. Schulz, B. Schulz, Barbara Schulz, N. Seybold, Schulz, Barbara

47

Publications

743

Citations

10

H-Index

12

Concepts

All Affiliations

Novartis (Switzerland)Ruhr University BochumRheumazentrum RuhrgebietUniversity of OxfordNovartis (India)
BS

About

Barbara Schulz is an author at Novartis (Switzerland) specializing in medicine, immunology, and dermatopathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

158

2

Immunology

1

1

121

3

Pharmacology

1

1

37

4

Cell Signaling

1

1

121

5

Immune Regulation

1

1

121

Barbara Schulz

×

11

Publications

700

Citations

10

H-Index

YearCitations

Omega-3 Fatty Acids and Low Carbohydrate Diet for Maintenance of Remission in Crohn's Disease: A Randomized Controlled Multicenter Trial

H. Lorenz‐Meyer, Peter Bauer, Claudia Nicolay,

Scandinavian Journal of Gastroenterology

1996

217

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial

Xenofon Baraliakos, Laure Gossec, Effie Pournara,

Annals of the Rheumatic Diseases

2020

178

Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro.

Barbara Schulz, G Michel, Stephan N. Wagner,

The Journal of Immunology

1993

121

Suspected side effects of doxycycline use in dogs – a retrospective study of 386 cases

Barbara Schulz, S. Hupfauer, Hermann Ammer,

Veterinary Record

2011

37

Management of pain in individuals with spinal cord injury: Guideline of the German-Speaking Medical Society for Spinal Cord Injury

Steffen Franz, Barbara Schulz, Haili Wang,

PubMed

2019

32

Pharmacokinetics of enrofloxacin and its efficacy in comparison with doxycycline in the treatment of <i>Chlamydophila felis</i> infection in cats with conjunctivitis

N. Gerhardt, Barbara Schulz, Christiane Werckenthin,

Veterinary Record

2006

31

OP0235 SECUKINUMAB IMPROVES AXIAL MANIFESTATIONS IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NSAIDS: PRIMARY ANALYSIS OF THE MAXIMISE TRIAL

Xenofon Baraliakos, Laura C. Coates, Laure Gossec,

Annals of the Rheumatic Diseases

2019

25

Secukinumab demonstrated sustained retention, effectiveness and safety in a real‐world setting in patients with moderate‐to‐severe plaque psoriasis: long‐term results from an interim analysis of the <scp>SERENA</scp> study

Matthias Augustin, Paul-Gunther Sator, Ralph von Kiedrowski,

Journal of the European Academy of Dermatology and Venereology

2022

23

Magnetic resonance imaging characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort

Xenofon Baraliakos, Effie Pournara, Laura C. Coates,

Lara D. Veeken

2023

14

Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab

Uta Kiltz, Petros P. Sfikakis, Karl Gaffney,

Rheumatology and Therapy

2022

12

Page 1